NHS England approves "Trojan horse" cancer therapy

The NHS will be the first health system globally to offer a new "Trojan horse" cancer treatment, potentially extending the lives of blood cancer patients. The treatment, belantamab mafodotin, is approved for use in England for multiple myeloma patients whose cancer has progressed or not responded to other treatments, and can delay disease progression by up to three years. Approximately 1,500 patients annually are expected to benefit. The drug, administered via infusion, targets cancer cells and releases a lethal molecule. Trials showed significantly improved outcomes compared to existing treatments, offering patients more time with loved ones.